Evidence map›Paper›PMID 30288644›Full record

ArticleNeurochemical research2018

SMER28 Attenuates Dopaminergic Toxicity Mediated by 6-Hydroxydopamine in the Rats via Modulating Oxidative Burdens and Autophagy-Related Parameters.

Shahram Darabi, Ali Noori-Zadeh, Farzad Rajaei, Hojjat Allah Abbaszadeh, Salar Bakhtiyari, Navid Ahmady Roozbahany

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Shahram DarabiCellular and Molecular Research Center, Qazvin University of Medical Sciences, P.O. BOX: 59811-34197, Qazvin, Iran. shahram2005d@yahoo.com.ORCID http://orcid.org/0000-0002-9405-6640
Ali Noori-ZadehDepartment of Clinical Biochemistry, Faculty of Paramedicine, Ilam University of Medical Sciences, Ilam, Iran.
Farzad RajaeiCellular and Molecular Research Center, Qazvin University of Medical Sciences, P.O. BOX: 59811-34197, Qazvin, Iran.
Hojjat Allah AbbaszadehHearing Disorders Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Salar BakhtiyariDepartment of Clinical Biochemistry, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Navid Ahmady RoozbahanyRaymond Chang School, Ryerson University, Toronto, Canada.
Medical University of Ilam · IRQazvin University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IRToronto Metropolitan University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease is the second most common neurodegenerative disease that occurs due to cellular autophagy deficiency and the accumulation of alpha-synuclein in the dopaminergic neurons of the substantia nigra pars compacta (SNc) of the brainstem. The SMER28 (also known as 6-Bromo-N-prop-2-enylquinazolin-4-amine) is an autophagy inducer. In this study, the neuroprotective effects of SMER28 were evaluated on autophagy induction, antioxidant system activation, and microgliosis attenuation. The Parkinson's disease model was developed in the male Wistar rats by injection of 6-OHDA into the left striatum. Apomorphine-induced behavior assessment test and SNc cell counting were performed to investigate the neuroprotective effects of SMER28. This study examined the pharmacological roles of SMER28, especially by focusing on the autophagy (p62/ SQSTM1 and LC3II/LC3I ratio where LC3 is microtubule-associated protein 1A/1B-light chain 3), inhibiting free radicals, and activating the antioxidant system. The levels of malondialdehyde (MDA), reactive oxygen species (ROS), glutathione (GSH), GSH/glutathione peroxidase (GP

Indexed as

Allyl CompoundsAnimalsAutophagyDopamineDopaminergic NeuronsMaleNeuroprotective AgentsOxidative StressOxidopamineParkinsonian DisordersQuinazolinesRandom AllocationRatsRats, Wistar6-bromo-4-allylamino-quinazolineAllyl CompoundsDopamineNeuroprotective AgentsOxidopamineQuinazolinesDopaminergic neuronsNrf2Parkinson’s diseaseSMER28SOD

Identifiers

PMID30288644
OpenAlexW2894597495

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.